Cargando…

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity

Immunotherapy is a rapidly expanding field of oncology aimed at targeting, not the tumor itself, but the immune system combating the cancerous lesion. Of the many approaches currently under study to boost anti-tumor immune responses; modulation of immune co-receptors on lymphocytes in the tumor micr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bartkowiak, Todd, Curran, Michael A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459101/ https://www.ncbi.nlm.nih.gov/pubmed/26106583 http://dx.doi.org/10.3389/fonc.2015.00117

Ejemplares similares

A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
por: Compte, Marta, et al.
Publicado: (2018)

Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy
por: Song, Chang, et al.
Publicado: (2014)

4-1BB: A promising target for cancer immunotherapy
por: Kim, Alyssa Min Jung, et al.
Publicado: (2022)

An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation
por: Muik, Alexander, et al.
Publicado: (2022)

Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies
por: Mikkelsen, Kasper, et al.
Publicado: (2019)

A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity
por: Cheng, Lian-sheng, et al.
Publicado: (2022)

The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
por: Nelson, Michelle H., et al.
Publicado: (2023)

Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity
por: Hangiu, Oana, et al.
Publicado: (2022)

Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma
por: Wang, Yichen, et al.
Publicado: (2022)

Combination of 4-1BB and DAP10 promotes proliferation and persistence of NKG2D(bbz) CAR-T cells
por: Wei, Cheng, et al.
Publicado: (2022)

Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
por: Curran, Michael A., et al.
Publicado: (2011)

PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody
por: Escuin-Ordinas, Helena, et al.
Publicado: (2013)

The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
por: Claus, Christina, et al.
Publicado: (2023)

Evaluating the Cellular Targets of Anti-4-1BB Agonist Antibody during Immunotherapy of a Pre-Established Tumor in Mice
por: Lin, Gloria H. Y., et al.
Publicado: (2010)

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
por: Hamid, Omid, et al.
Publicado: (2022)

PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB “Super-Stimulation”
por: Zuccolotto, Gaia, et al.
Publicado: (2021)

A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity
por: Thiemann, Meinolf, et al.
Publicado: (2018)

Intra-Tumoral Activation of Endosomal TLR Pathways Reveals a Distinct Role for TLR3 Agonist Dependent Type-1 Interferons in Shaping the Tumor Immune Microenvironment
por: Thomas, Graham, et al.
Publicado: (2021)

DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
por: Muik, Alexander, et al.
Publicado: (2022)

Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model
por: Schrörs, Barbara, et al.
Publicado: (2020)

Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications
por: Salek-Ardakani, Shahram, et al.
Publicado: (2023)

Correction: DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
Publicado: (2022)

Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
por: Qi, Xinyue, et al.
Publicado: (2019)

Tumor hypoxia drives immune suppression and immunotherapy resistance
por: Ai, Midan, et al.
Publicado: (2015)

Covalently Conjugated NOD2/TLR7 Agonists Are Potent and Versatile Immune Potentiators
por: Guzelj, Samo, et al.
Publicado: (2022)

Potential Impact of ALKBH5 and YTHDF1 on Tumor Immunity in Colon Adenocarcinoma
por: Yan, Guanyu, et al.
Publicado: (2021)

Targeting 4-1BB for tumor immunotherapy from bench to bedside
por: Wang, Ya-Tao, et al.
Publicado: (2022)

Relationship between copper and immunity: The potential role of copper in tumor immunity
por: Cheng, Fu, et al.
Publicado: (2022)

Editorial: Advances in Combination Tumor Immunotherapy
por: Curran, Michael A., et al.
Publicado: (2015)

LAG-3 and 4-1BB identify dysfunctional antigen-specific T cells in the tumor microenvironment and combinatorial LAG-3/4-1BB targeting gives synergistic tumor control
por: Williams, Jason B, et al.
Publicado: (2015)

OX40 and 4-1BB delineate distinct immune profiles in sarcoma
por: Melake, MJ, et al.
Publicado: (2022)

Resveratrol and Its Analogs: Potent Agents to Reverse Epithelial-to-Mesenchymal Transition in Tumors
por: Guo, Kaibo, et al.
Publicado: (2021)

Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity
por: Guo, Zong Sheng, et al.
Publicado: (2014)

A NOVEL MSLN×4-1BB BISPECIFIC ANTIBODY FOR SOLID TUMOR
por: Cheng, Liansheng, et al.
Publicado: (2023)

Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer
por: Trüb, Marta, et al.
Publicado: (2020)

Tim-3 Blockade Elicits Potent Anti-Multiple Myeloma Immunity of Natural Killer Cells
por: Jiang, Wen, et al.
Publicado: (2022)

Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin
por: Curran, Michael A., et al.
Publicado: (2013)

Agonist anti-4-1BB plus neutralizing anti-CTLA-4 or -PD-L1 synergize to promote tumor regression by rescuing dying dysfunctional CD8+ T cells within the tumor microenvironment
por: Horton, Brendan, et al.
Publicado: (2015)

Involvement of Platelet–Tumor Cell Interaction in Immune Evasion. Potential Role of Podocalyxin-Like Protein 1
por: Amo, Laura, et al.
Publicado: (2014)

Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context
por: Czapla, Justyna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2gs5ms2l470vofglekafomr5ko